Results 41 to 50 of about 6,081 (225)
Frontiers in Pharmacology, 2022 Background: Aortic stenosis (AS) increases left ventricular afterload, leading to cardiac damage and heart failure (HF). Transcatheter aortic valve replacement (TAVR) is an effective therapy for AS.
Zhenyan Zhao +12 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García +17 more
wiley +1 more source
Use of Levosimendan in Cardiac Anesthesiology
Общая реаниматология, 2011 The authors consider the main aspects of the rational use of the novel inotropic drug levosimendan in cardiosurgical patients on the basis of the results of the trials described in the literature and on their own findings in this review.
L. A. Krichevsky +4 more
doaj +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
FEBS Open Bio, 2021 ATP‐sensitive potassium channels (KATPs) have protective effects in ischemia–reperfusion‐induced injuries and can be activated by levosimendan. This study investigated the effects of levosimendan on renal injury, inflammation, apoptosis, and survival in ...
Lei Tian +6 more
doaj +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse‐coordinated multidisciplinary comprehensive HF management programme on HF patients.
Cecilia Miu‐Ching Chan +13 more
wiley +1 more source
Worsening versus advanced heart failure: Management and challenges
ESC Heart Failure, EarlyView.Clinical feature, circulating biomarkers and therapeutic management of patients with WHF versus AdvHF. Abbreviations: AdvHF, advanced heart failure; HF, heart failure; HTx, heart transplant; GDMT, guideline‐directed medical therapy; MCS, mechanical circulatory support; NYHA, New York Heart Association; WHF, worsening heart failure.
Alberto Palazzuoli +15 more
wiley +1 more source
Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. [PDF]
PLoS ONE, 2014 Levosimendan, a known calcium sensitizer with positive inotropic and vasodilating properties, might also be cardioprotective during ischemia-reperfusion (I/R) insult. Its effects on calcium homeostasis and apoptosis in I/R injury remain unclear. Na(+)/Ca(
Ping-Chun Li +4 more
doaj +1 more source
ESC Heart Failure, EarlyView.Among patients with ADHF‐related SCAI stage B CS enrolled in SEISMiC, istaroxime at doses up to 1.0 μg/kg/min for up to 60 h was associated with sustained improvements in aortic pulsatility index and LV stroke work index, and with increase of PA compliance and reduction in PA elastance at 48 h.
Matteo Pagnesi +21 more
wiley +1 more source
European Journal of Heart Failure, EarlyView.Kidney injury in heart failure‐related cardiogenic shock. AKI, acute kidney injury; CI, confidence interval; eCPR, extracorporeal cardiopulmonary resuscitation; eGFR, estimated glomerular filtration rate; HR, hazard ratio; OR, odds ratio; VA‐ECMO, veno‐arterial extracorporeal membrane oxygenation.
Jonas Sundermeyer +41 more
wiley +1 more source